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Nongenotropic, Sex-Nonspecific Signaling
through the Estrogen or Androgen Receptors:
Dissociation from Transcriptional Activity
from those that mediate the transcriptional effects of the
steroids. Moreover, the relationship of nongenotropic
effects of steroids to the transcriptional activity of the
classical receptors is completely unknown.
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gen deficiency (Riggs et al., 1998; Vanderschueren et
al., 1998). To date, there is no explanation for theseThe relationship of the classical receptors and their
seemingly paradoxical observations.transcriptional activity to nongenotropic effects of ste-
Herein, we demonstrate a potent antiapoptotic effectroid hormones is unknown. We demonstrate herein a
of estrogens and androgens on murine osteoblasts andnovel paradigm of sex steroid action on osteoblasts,
osteocytes in vitro and in vivo. We show that this effectosteocytes, embryonic fibroblasts, and HeLa cells in-
is due to activation of an Src/Shc/ERK signaling pathwayvolving activation of a Src/Shc/ERK signaling pathway
via a nongenotropic action of the classical receptorsand attenuating apoptosis. This action is mediated by
which, unlike their well known specificity in transcrip-the ligand binding domain and eliminated by nuclear
tional effects, is sex nonspecific and eliminated by nu-targeting of the receptor protein; ERa, ERb, or AR
clear targeting. In addition, we show that this antiapo-can transmit it with similar efficiency irrespective of
ptotic effect is dissociable from the transcriptionalwhether the ligand is an estrogen or an androgen.
activity of the classical receptors.This antiapoptotic action can be dissociated from the
transcriptional activity of the receptor with synthetic
ligands, providing proof of principle for the develop- Results
ment of function-specific—as opposed to tissue-selec-
tive—and gender-neutral pharmacotherapeutics. Regulation of Osteoblast and Osteocyte
Apoptosis by Estrogen or Androgen
In Vivo and In VitroIntroduction
Ovariectomy or orchidectomy in mice increased verte-
bral osteoblast apoptosis by 10- and 8.3-fold and osteo-The effects of sex steroids are mediated through recep-
tor proteins, which, by and large, discriminate between cyte apoptosis by 4- and 3.5-fold, respectively, com-
pared to sham-operated controls (Figure 1A). Theseestrogen and androgen signaling and are distributed in
a sex-specific pattern among female and male target changes were prevented in ovariectomized mice receiv-
ing 17b-estradiol (E2) (data not shown). To elucidate theorgans, respectively. Binding of the steroids to their
respective receptors leads to conformational changes mechanism of these effects, we used primary calvaria
cell cultures and an osteocytic cell line as in vitro mod-of the protein that allow it to interact with the transcrip-
tional machinery directly, or indirectly via protein– els. Either E2, or 5a-dihydrotestosterone (DHT) inhibited
etoposide-induced apoptosis in calvaria cells in a dose-protein interactions with other transcription factors.
Nonetheless, a variety of cell types respond to estro- dependent fashion with a maximal effect seen at 1029
to 1028 M (Figure 1B); identical results were obtainedgens rapidly, making a genomic mechanism of action
unlikely (McEwen and Alves, 1999). Many of these rapid with MLO-Y4 cells (not shown). E2 or DHT prevented
apoptosis of calvaria-derived murine osteoblastic cellsactions have been attributed to the ability of estrogens
to interact with a putative membrane-associated estro- (Figure 1C) or the osteocytic cell line MLO-Y4 (Figure
1D) when induced by any of three different proapoptoticgen receptor (ER) (Watson and Gametchu, 1999). How-
ever, it is uncertain whether these nongenotropic effects stimuli: etoposide, dexamethasone, or TNFa; as well as
Fas-Fas ligand (not shown).are mediated by proteins that are the same as or distinct
The signals that control the prevalence of apoptosis
of osteoblasts and osteocytes in vivo are unknown.‡ To whom correspondence should be addressed (e-mail: manola
However, there is extensive evidence to suggest thatgasstavros@uams.edu).
§ These authors contributed equally to this work. interactions of cells with their matrix, in particular colla-
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Figure 1. Control of Osteoblast and Osteocyte Apoptosis by Sex Steroids In Vivo and In Vitro
(A) Prevalence of osteoblast and osteocyte apoptosis following ovariectomy or orchidectomy in mice. Bars are means 6 SD of 4–5 animals
per group. *p , 0.05.
(B) Calvarial osteoblasts were treated for 1 hr with 10211 M to 1026 M of E2 or DHT followed by 6 hr treatment with the proapoptotic agent
etoposide (50 mM). The percentage of dead cells was quantified by trypan blue staining. Bars indicate means 6 SD of triplicate determinations,
*p , 0.05 for E2- or DHT-treated cultures versus vehicle using separate one-way ANOVAs for each treatment.
(C and D) Calvaria-derived osteoblasts or MLO-Y4 osteocytic cells were treated with 1028 M E2 or DHT, and apoptosis was induced by addition
of etoposide, dexamethasone (1027 M), or TNFa (1 nM). The percentage of dead cells was quantified as in (B). Results were analyzed by two-
way ANOVA. *p , 0.05 when comparing pretreatments within each agent group and each agent versus vehicle for a given pretreatment.
(E) OB-6 osteoblastic cells incorporated into collagen gels were treated with different concentrations of E2 or DHT for 24 hr. A total of 200
cells were evaluated in randomly selected fields. In vehicle controls, 32.3 6 2.5% of the cells were apoptotic. *p , 0.05 for E2- or DHT-treated
cultures versus vehicle using separate one-way ANOVAs for each treatment.
gen–integrin interactions, are important in vivo cues for we studied the effects of sex steroids on anoikis using
a bone-marrow-derived osteoblastic cell line (OB-6),the decision of a cell to survive or initiate the process
of suicide by apoptosis. This phenomenon has been which was cultured inside type I collagen gels (Figure
1E). In this system, apoptosis results from loss of integrintermed anoikis (Frisch and Ruoslahti, 1997). Therefore,
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signaling during contraction of the collagen lattice. As
in the case of the other proapoptotic signals, either E2
or DHT dose dependently attenuated anoikis at concen-
trations as low as 10211 M.
ER (a or b) or the AR Transmit Antiapoptotic
Signals with the Same Efficiency Irrespective
of whether the Ligand Is an Estrogen
or an Androgen
The estrogen receptor antagonist ICI 182,780 or the
androgen receptor antagonist flutamide blocked the
antiapoptotic effect of E2 and DHT in calvaria cells, sug-
gesting strongly that the effects of the sex steroids were
mediated by the ER and AR. Surprisingly, however, the
antiapoptotic effect of E2 was also abrogated by fluta-
mide, and the effect of DHT by ICI 182,780 (Figure 2A).
Consistent with this unexpected result, others have
shown previously that anti-hormones including ICI
182,780 interact with multiple classes of steroid recep-
tors (Nawaz, 1999).
To establish the dependency of the antiapoptotic ef-
fect of E2 and DHT on the ER and AR and dissect the
role of each receptor in the unexpected results with the
antagonists, we next performed studies with HeLa cells,
which do not express ER or AR. In these experiments,
HeLa cells were transiently transfected with enhanced
green fluorescent protein containing a nuclear localiza-
tion sequence (Nuc-EGFP) and either ERa, ERb, or the
AR expression constructs, or empty vector controls (Fig-
ure 2B). Neither E2 nor DHT (10212 M to 1028 M) had an
effect on etoposide-induced apoptosis in cells trans-
fected with the vector without receptor (empty vector,
ev). However, in HeLa cells transfected with either the
Figure 2. The Antiapoptotic Effects of E2 or DHT Are Inhibited by
ER (a or b) or the AR, but not the vitamin D recep- Both ER or AR Antagonists and Can Be Mediated via Either the ER
tor (VDR) or the retinoid X receptor (RXR), both E2 or (a or b) or the AR
DHT prevented apoptosis in a dose-dependent manner (A) Calvarial osteoblasts were pretreated with the ER antagonist ICI
over the same range of concentrations. Interestingly, 182,780 (1027 M) or with the AR antagonist flutamide (1027 M) for
30 min, followed by incubation with 1028 M E2 or DHT for 1 hr.1,25(OH)2D3 prevented apoptosis in HeLa cells trans-
Subsequently, etoposide was added and apoptotic cells were quan-fected with the VDR or RXR, but not the ERs or the AR.
tified after 6 hr as in Figure 1B. Bars indicate means 6 SD of triplicateIdentical results were obtained using dexamethasone
determinations, *p , 0.05 versus vehicle, by ANOVA.
to induce apoptosis. (B) HeLa cells were transiently transfected with either ERa, ERb,
As in the experiments with the primary cultures of AR, VDR, or RXR expression vectors or with the empty vector (ev),
osteoblastic cells, either ICI 182,780 or flutamide abro- along with a Nuc-EGFP expression vector. Sixteen hours after trans-
fection, cells were treated with the indicated concentrations of E2,gated the effect of E2 or DHT in HeLa cells, irrespective
DHT, or 1,25-dihydroxy-Vitamin D3 (1,25D3) for 1 hr followed by 6of whether the HeLa cells were transfected with the ERa
hr treatment with etoposide. *p , 0.05 versus cells treated withor the AR (data not shown).
etoposide in the absence of steroids (2), by ANOVA .
The Antiapoptotic Activity of the ERa Is Located
within the E (Ligand Binding) Domain and Requires nal transcription activation function (AF-1) domain, or a
mutant in which serines were substituted with alanineExtranuclear Localization of the Protein
Using the ERa as a prototype, we next sought to deter- (S104,106,118A), or mutant DF, which lacks the F do-
main, or mutant DDBD which lacks most of the DNAmine whether the antiapoptotic activity of the receptors
for sex steroids requires the same or different domains binding domain (amino acids 185–251), were able to
convey the antiapoptotic signal of the E2-bound ER. Yetas those required for transcriptional activity (Figure 3A).
To do this, we compared the effects of several mutants all these mutants exhibit reduced or no ERE-mediated
gene transcriptional activity (Le Goff et al., 1994; McIner-of the ERa on prevention of apoptosis. These mutants
have been shown to produce the expected proteins ney and Katzenellenbogen, 1996; Katzenellenbogen et
al., 2000). More striking, the ability of the ligand to con-when transiently transfected into human cells (Schodin
et al., 1995; Ekena et al., 1996; Kraus et al., 1997). In vey the antiapoptotic signal was preserved in a deletion
mutant which is missing the entire AF-1 and DNA bindingexperiments not shown, we established that the mutants
comprising the DE or E domains also produced the ex- domain (DE); as well as in a deletion mutant consisting
solely of the AF-2/ligand binding domain (E). In contrast,pected proteins and lacked transcriptional activity.
Like ERa, mutant DA/B, which lacks the entire N-termi- the ER mutant L525A, which lacks hormone binding
Cell
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Figure 3. Localization of the Antiapoptotic Activity of the ERa to the E (Ligand Binding) Domain: Elimination by Nuclear Targeting
(A) HeLa cells were cotransfected with expression vectors for Nuc-EGFP and various ERa mutants, and then treated for 1 hr with 1028 M E2
followed by 6 hr treatment with etoposide.
(B) The full-length ERa was fused to the nontargeted ECFP (ERa-ECFP). The E domain of the ERa was fused to either nontargeted ECFP
(E-ECFP), membrane-targeted ECFP (E-Mem-ECFP), or nuclear-targeted ECFP (E-Nuc-ECFP). Each of these fusion proteins was expressed
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ability and S554fs (which is deficient in the C-terminal Fyn (Soriano et al., 1991), unlike the Src1/1 wild-type
controls, were unresponsive to the antiapoptotic effecttranscription activation function [AF-2]), lost the ability
to convey both the antiapoptotic signal and the tran- of E2 or DHT (Figure 4B).
The codependency of the antiapoptotic effect of E2scriptional activity of the protein (Schodin et al., 1995;
Ekena et al., 1996). and DHT on the sex steroid receptors (either the ER or
AR) as well as on the activation of a Src/ERK signalingWe next determined whether the antiapoptotic activity
of the E domain was dependent on its localization to pathway was demonstrated in HeLa cells (Figures 4C
and 4D). PD98059 or cotransfection of a dominant-nega-a particular subcellular compartment (Figure 3B). We
targeted this domain to the plasma membrane or to the tive (dn) MEK, a kinase responsible for the phosphoryla-
tion of ERKs, abrogated the effects of E2 or DHT innucleus of HeLa cells by fusing it to enhanced cyan
fluorescent protein containing plasma membrane or nu- HeLa cells transfected with the ERa or AR (Figure 4C).
Likewise, the effect of E2 or DHT was abrogated in HeLaclear localization sequences, respectively. As revealed
by epifluorescence microscopy, the nontargeted ERa cells transfected with the ERa or AR and cotransfected
with a Src mutant lacking the kinase activity (Src K2)and the nontargeted E exhibited similar distribution of
cyan fluorescence in the nucleus and cytoplasm, indi- (Figure 4D). More strikingly, a Src mutant lacking the
SH2 domain (Src DSH2) abrogated the antiapoptoticcating that elimination of all but the ligand binding do-
main of the ER does not alter the subcellular distribution. activity of ligand-activated ERa but not that of the AR.
Conversely, a Src mutant lacking the SH3 domain (SrcHowever, incorporation of the appropriate targeting se-
quences accomplished the expected subcellular local- DSH3) abrogated the antiapoptotic activity of the AR
but not of the ER. These results are in line with theization of the membrane or the nuclear ECFP fusion
proteins, respectively, as can be seen from the distribu- findings of Migliaccio et al., that Src SH2 interacts with
the ER and the Src SH3 domain with the AR (Migliacciotion of cyan and red fluorescence in the same cell(s).
Targeting the E domain predominantly to the plasma et al., 2000). Further, the antiapoptotic activity of the
E2- or DHT-activated ERa was abrogated by dominant-membrane did not alter its ability to convey the ligand-
induced antiapoptotic signal, as evidenced by identical negative Shc mutants in which all three, or only the third
of the three tyrosines (Y239, Y240, and Y317), which areantiapoptotic activity of this fusion protein to that of the
E domain or the full-length ERa. But in sharp contrast, the primary sites of Shc phosphorylation, were substi-
tuted by phenylalanine. However, when tyrosines 239targeting the E domain exclusively to the cell nucleus
resulted in complete loss of its antiapoptotic activity. and 240, but not 317, were mutated, the antiapoptotic
activity of the receptor was unaffected (Figure 4E).
Consistent with the evidence that the E domain of theThe Antiapoptotic Activity of the ER and AR Is
ER is sufficient for its antiapoptotic activity (Figure 3),Mediated via a Src/Shc/ERK Signaling Pathway
in HeLa cells transfected with this domain, PD98059,E2 or DHT rapidly and transiently increased the phos-
the dn MEK, the Src K2, Src DSH2, or Src DSH3 hadphorylation of ERKs in MLO-Y4 cells, with a maximal
exactly the same effects as they did in the HeLa cellseffect seen at 5 min and a return to baseline by 15 min
transfected with the full-length ERa (Figures 4C and 4D).(Figure 4A). Identical results were reproduced using the
murine calvaria osteoblastic cells (not shown). The in-
duction of ERK phosphorylation by E2 or DHT was Dissociation of the Transcriptional from the
Antiapoptotic Activity of the ERa Usingblocked by the specific inhibitors of the phosphorylation
of ERKs, PD98059 and U0126 (not shown). Migliaccio Peptide Antagonists and Synthetic Ligands
McDonnell and coworkers have previously isolated sev-and colleagues have recently reported that the estrogen
and androgen receptors complex with Src, and that this eral classes of small (11–19 amino acid) peptides that
bind distinct sites of the ligand-activated ER, and canevent leads to ERK-2 activation and prostate cancer cell
proliferation (Migliaccio et al., 2000). In agreement with selectively block ERa but not ERb-mediated transcrip-
tion, and vice versa, when tested on a consensus EREthat report, E2- or DHT-induced ERK phosphorylation in
our experiments was blocked by the Src family tyro- (estrogen response element) (Chang et al., 1999; Norris
et al., 1999). Using such peptides, we examined heresine kinase inhibitor PP1 (Figure 4A). Moreover, both
PD98059 and PP1 completely abrogated the antiapo- whether they block the antiapoptotic effects of E2 (Figure
5). In parallel experiments, the ability of these peptidesptotic effects of E2 and DHT, indicating that ERK phos-
phorylation and Src kinase activity are required for the to block transcription was examined using HeLa cells
transfected with an ERE-driven luciferase constructantiapoptotic effects of both sex steroids. Confirmatory
evidence for the essential role of Src kinase in the anti- (ERE-Luc) or an IL-6 promoter-driven luciferase (IL-
6-Luc). The peptide designated aII, which binds toapoptotic effects of sex steroids was provided by the
finding that ER- and AR-expressing embryonic fibro- the ligand binding domain of the ERa, blocked the
E2-induced increase in ERE-Luc transcription (Figure 5A).blasts derived from Src2/2 mice that also lack Yes and
in HeLa cells along with a nuclear targeted red fluorescent protein (Nuc-ERFP) and their subcellular distribution was analyzed by epifluorescence
microscopy. Left and middle panels depict photomicrographs of the same cell(s) obtained with either cyan or red filter sets, respectively;
bar 5 15 mm. Nuc-ERFP was used in this experiment to quantify apoptosis because its emission can be readily distinguished from that of
the cyan fusion proteins. Transfected cells were treated for 1 hr with 1028 M E2 or vehicle followed by 6 hr treatment with etoposide. Apoptosis
in both (A) and (B) was quantified as in Figure 2. Bars indicate means 6 SD of triplicate determinations. *p , 0.05 versus cells not treated
with etoposide by ANOVA.
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Figure 5. Dissociation of ERa-Mediated Tran-
scriptional versus Antiapoptotic Actions and
ERa-Mediated versus ERb-Mediated Effects
Using Peptides
(A) HeLa cells were transiently transfected
with the ERa expression vector alone or to-
gether with a vector carrying a fusion of the a-II
peptide with the GAL4 DNA binding domain
driven by the SV40 promoter. In addition, cells
were transfected with ERE-luc or IL-6-luc for
the transcription studies; or with Nuc-EGFP
for the apoptosis experiments. Bars repre-
sent the mean 6 SD of triplicate determina-
tions and indicate fold-stimulation of ERE-
luc, or fold-inhibition of IL-6-luc, or % of
transfected cells with apoptotic features in
vehicle (E22) or 1028 M E2 (E21). *p , 0.05
versus vehicle-treated cells, by ANOVA.
(B) HeLa cells were transfected with ERa or
ERb alone or together with expression vec-
tors carrying 2x293 or 2xF6 peptides. Bars
represent mean 6 SD of triplicate determina-
tions of the activity (ERE-luc, IL-6-luc, or anti-
apoptosis) in response to E2 (1028 M) in cells
transfected with the indicated receptor and
peptide versus cells transfected with the re-
ceptor alone. E2-induced activity in cells car-
rying the receptor, but not the peptide, was
designated as 100%. *p , 0.05 versus cells
transfected with the receptor alone, by
ANOVA.
(C) HeLa cells were transfected with a vector
carrying the GRIP peptide alone or together
with ERa. Bars represent the mean 6 SD of
triplicate determinations. *p , 0.05 versus ve-
hicle treated cells, by ANOVA.
Likewise, this peptide blocked an E2-induced decrease did block the antiapoptotic activity of the ERb, but it
did not have an effect on the antiapoptotic activity ofin the transcription of IL-6—a paradigm of transcrip-
tional regulation mediated via protein–protein interac- the ERa. F6 blocked the antiapoptotic activity of both
ERa and ERb, as well as transcription from ERE and IL-6.tion between the ER and other transcription factors.
Nonetheless, the aII peptide did not influence the anti- The transcriptional activity of the ER is dramatically
influenced by its interaction with specific coactivators,apoptotic effect of E2. Identical results were obtained in
experiments using HEK293 instead of HeLa cells (not most of which contain the conserved LXXLL motif
termed the nuclear receptor box (McKenna et al., 1999).shown).
An ERb-specific peptide (293) blocked the effect of Peptide GRIP prevents the interaction of the ER with
GRIP-1, one of these coactivators (Chang et al., 1999).E2 on transcription from both the ERE and the IL-6 pro-
moters in the ERb-carrying cells, but not in the ERa- When this peptide was cotransfected with ERa into
HeLa cells, it did not influence the antiapoptotic activitycarrying cells (Figure 5B). On the other hand, a peptide
which interacts with both the ERa and ERb (F6) blocked of the ER (Figure 5C), arguing further that the antiapo-
ptotic activity of the ligand-activated receptor is inde-the effect of E2 on transcription from ERE or IL-6 in both
ERa- and ERb-carrying cells. More importantly, unlike pendent of the function of this protein as a nuclear tran-
scription factor.aII, which did not affect the antiapoptotic activity of ERa
(and as expected of ERb, as aII is specific for ERa), 293 Finally, we sought evidence that the transcriptional
Figure 4. The Antiapoptotic Activity of the ER and AR Is Mediated via a Src/Shc/ERK Signaling Pathway
(A) MLO-Y4 cells were incubated for 2, 5, or 15 min with E2 or DHT or for 25 min with PD98059 (50 mM) or PP1 (10 mM) followed by 5 min
with E2 or DHT, and ERK1/2 phosphorylation was analyzed by Western blotting. For the determination of apoptosis, cells were incubated with
vehicle, PD98059, or PP1 30 min prior to the addition of E2 or DHT. After 30 min, etoposide was added and apoptosis was assayed 6 hr later
as in Figure 1B.
(B) The effect of E2 or DHT on apoptosis was compared in embryonic fibroblasts from Src1/1 versus Src2/2 mice, as described in Figure 1B.
RT-PCR was performed as described in the Experimental Procedures.
(C–E) HeLa cells were transfected with Nuc-EGFP and with expression vectors encoding the full-length ERa or its E domain, or the AR alone
(C, left panel) or together with a dn MEK (C, right panel); a Src mutant lacking the kinase activity (Src K2), a Src mutant lacking the SH2
domain (Src DSH2), or a Src mutant lacking the SH3 domain (Src DSH3) (D); or with ERa together with wt Shc, or the dn Shc mutants Y239F/
Y240F/Y317F (Shc FFF), Y317F (Shc YYF), or Y239F/Y240F (Shc FFY) (E) Bars represent means 6 SD of triplicate determinations. *p , 0.05
versus cells cultured without steroids, by ANOVA .
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Figure 6. Dissociation of Nongenotropic from
Genotropic Activity of the ER with Synthetic
Ligands
(A) For C3-mediated transcription, HeLa cells
were transfected with C3-luc and ERa, and
were treated with the indicated concentra-
tions of an estren or a pyrazole. Bars repre-
sent the mean 6 SD of the relative luciferase
units (RLU) normalized for b-galactosidase
activity. *p , 0.05 versus cells transfected
with empty vector (ev), by ANOVA. The anti-
apoptotic activity of the estren and the pyra-
zole was evaluated in calvaria-derived osteo-
blasts as described in Figure 1B. *p , 0.05
versus cells not treated with etoposide by
ANOVA.
(B) MLO-Y4 cells were incubated for 5 min
with the indicated concentrations of the dif-
ferent ligands and ERK phosphorylation was
assessed as in Figure 4A.
activity of the ERa could be dissociated from its nongen- Biologic effects of the nuclear orphan receptor TR3
and the ER, which are independent of their transcrip-otropic activity with synthetic ligands. This was accom-
plished by comparing the effects of various ligands on tional activity in the nucleus, have been recently re-
ported (Li et al., 2000; Simoncini et al., 2000). In addition,the transcription of the C3 gene, which contains an ERE
in its promoter and is regulated by estrogen in a classical Migliaccio et al. demonstrated that ER or AR coimmuno-
precipitate with Src in prostate cancer cells. Based onmanner, with their antiapoptotic effect on primary cal-
varia cells. As depicted in Figure 6A, we found that an this, they suggested that a ternary complex of ER, AR,
and Src may account for a cross talk between anti-estren, with no transcriptional activity, exhibited potent
antiapoptotic efficacy. On the other hand, a pyrazole estrogen and anti-androgen (Migliaccio et al., 2000). The
results presented herein argue strongly that the crosswith potent transcriptional activity had minimal antiapo-
ptotic efficacy. The relative antiapoptotic potency of talk between antagonists, and more important, the cross
talk between the cognate ligands—an issue that wasthese two compounds correlated with their ability to
induce ERK phosphorylation (Figure 6B). not addressed in the Migliaccio study—is not dependent
on the complexing of ER with AR, as prevention of apo-
ptosis by the heterologous ligand in our studies could beDiscussion
demonstrated in cells transfected with only one steroid
receptor. Nonetheless, we cannot exclude the possibil-We have demonstrated an antiapoptotic effect of sex
ity of alternative complexing partners of ER or AR in oursteroids on bone and other cell types, which is mediated
HeLa cell experiments, perhaps a promiscuous thirdvia a Src/Shc/ERK signaling cascade and a region of
receptor that may be activated by both androgens andthe classical receptor that is distinct from the one re-
estrogens, like the xenobiotic pregnane X receptorsponsible for the genotropic actions of the ligand-acti-
(Jones et al., 2000).vated protein. Indeed, using ERa as a paradigm, we
Several members of the MAP kinase signaling path-determined that this effect requires only the ligand bind-
ing domain. way, including Src, Shc, and ERKs, are clustered in
Unisex Signaling through Sex Steroid Receptors
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Figure 7. Proposed Model for Ligand-Induced
Dissociation of Antiapoptotic from Classical
Genotropic Activity of Sex Steroid Receptors
The three cartoons depict conformational
states of the receptor protein prior to and
following interaction with the ligands, which
are required to effect either the genotropic
or the antiapoptotic responses. The inactive
unliganded receptor is depicted in the middle
in gray. The change in conformation induced
by interaction with a ligand that preferentially
triggers transcriptional activity (e.g., the pyra-
zole of Figure 6) is depicted in the right in
blue. The change in conformation induced by
interaction with a ligand that preferentially
triggers the antiapoptotic activity of the re-
ceptor (e.g., the estren of Figure 6) is depicted
in the left in magenta. Green circle and green
diamond represent the two ligands; please
note the perfect and imperfect fit within the
binding pocket, respectively. Association (ka)
and dissociation (kd) rates of the two different
types of ligands for the receptor are depicted
by different width arrows. Ligands such as
E2 will of course induce both conformations.
Although in the antiapoptotic model we show
direct contact between the receptor and Src,
it is possible that adaptor protein(s) may bridge the interaction between the two molecules. Corresponding activation energy (Ea) of the
receptor protein in the unliganded state (broken line), progressing either to the genotropic conformation (blue line) or the antiapoptotic
conformation (magenta line) is shown in the bottom.
caveolae—specialized membrane invaginations that are conformational states, assumed by the receptor pro-
teins following their physical association with the ligand,enriched in the scaffolding protein caveolin-1 and com-
partmentalize signal transduction (Okamoto et al., 1998). that are required to effect the genotropic versus the
antiapoptotic responses (Figure 7).Caveolae are found in a variety of cell types includ-
ing osteoblasts (Solomon et al., 2000). ERa has been On the scale of molecular interactions and cellular
events, a genotropic response is a relatively long-termshown recently to coimmunoprecipitate with caveolin-1
(Schlegel et al., 1999). More to the point, a subpopulation one and thus is believed to require the classical ligand-
receptor interaction involving a detailed fit of the hor-of ERa has been colocalized in caveolae with both ca-
veolin and eNOS—an enzyme activated by estrogen mone in the binding pocket to produce a complex of
sufficient stability and lifetime to effect the multiple pro-through a nongenotropic mechanism of action (Cham-
bliss et al., 2000). The dependency of the antiapoptotic tein–protein and protein–nucleic acid interactions and
effect of estrogen and androgen on sex steroid recep- the enzymatic activations that are required to remodel
tors as well as Src, Shc, and ERKs, along with the evi- chromatin architecture and effect changes in the rate
dence that the antiapoptotic signal of the E domain of of gene transcription (Figure 7, blue structure). The need
the ER is preserved when targeting this protein to the to form such a stable, long-lived, ligand–receptor com-
membrane, but is lost when targeting it to the nucleus, plex places strict demands on ligand structure, leading
suggest strongly that the effect studied herein may be to the well-known specificity and distinct pharmacology
mediated via a fraction of the classical receptor that is that characterize the classical genotropic effects of es-
associated with the plasma membrane, probably within trogens and androgens.
caveolae. By contrast, ERK activation underlying the nongeno-
tropic antiapoptotic response is very rapid and may be
effected by a less fully developed or broader range ofDissociation of Nongenotropic from Genotropic
conformations adopted by much more transient ligand–Activity of Steroid Receptors and Its
receptor complexes (Figure 7, magenta structure). ThePharmacologic Implications
formation of such transient species might require merelyThe evidence presented in this report demonstrates that
that the ligand associates with the receptor briefly, andthe nongenotropic activity of a steroid receptor can be
thus would be dominated by ligand association rates,functionally dissociated from the genotropic activity of
rather than the ratio of association to dissociation ratesthis transcription factor and that this can be accom-
that determines the affinity of ligands assessed by clas-plished using synthetic steroidal or nonsteroidal com-
sical binding affinity assays. Because ligand associationpounds. At this stage, we do not know the mechanism
rates are much more comparable than dissociation ratesby which such compounds can preferentially induce one
(Raynaud et al., 1978; Bindal et al., 1987), the formationactivity over the other, nor can we definitively account
of such short-term complexes might show greatly re-for the sex-nonspecific nature and altered ligand po-
laxed structural specificity and potency/affinity ranking,tency rank of the antiapoptotic response. Nonetheless,
as is manifest in the antiapoptotic response. Futureit is tempting to speculate that ligand-induced dissocia-
tion of the two activities may be the result of distinct studies will be needed to address these issues, and new
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techniques may be required to study the formation of standing paradoxes, such as the low level of expression
and lack of gender dimorphism of ER and AR betweensuch transient, though potentially biologically meaning-
ful complexes. male and female bone cells, and the antiosteoporotic
efficacy of either class of sex steroids in females andThe idea that a ligand-induced rapid response may
exhibit a different potency order than a long-term re- males. In addition, we propose that dissociation of non-
genotropic from genotropic activities of the sex steroidsponse has interesting precedents. In the time course
of events that follows estrogen stimulation of the uterus receptors with synthetic ligands may provide novel
means of separating desirable from undesirable actionsof immature rats, short-acting estrogens such as estriol
and dimethylstilbestrol are equipotent with long-acting of sex steroids, thereby paving the way for improved
pharmacotherapeutic agents. Specifically, and basedestrogens such as estradiol and diethylstilbestrol in in-
ducing early responses such as water imbibition and on preliminary results of ours reported elsewhere (Mano-
lagas, 2000), we submit that mechanism-specific ligandsearly RNA synthesis, whereas they are far less potent
than the long-acting estrogens in inducing the later re- of the ERs or the AR, in distinction to tissue-specific li-
gands (SERMs) or classical estrogen or androgen, may besponses such as DNA synthesis and uterine growth (Kat-
zenellenbogen et al., 1978, 1979). Likewise, reminiscent an advantageous class of pharmacotherapeutic agents
(true anabolic as opposed to antiresorptive) and genderof the relaxed specificity shown here in the nongeno-
tropic response, several enzymes can be inhibited rap- neutral for the management of osteopenic states.
idly and effectively by a rather wide range of ligands,
Experimental Proceduresonly a few of which then proceed slowly to form much
more stable and long-lived complexes (Morrison, 1988;
Quantification of Apoptotic Osteoblasts and OsteocytesSzedlacsek, 1995).
in Undecalcified Bone Sections
Four-month-old female Swiss-Webster mice or five-month-old male
Relevance of Sex-Nonspecific Antiapoptotic SAMR1 mice were subjected to a sham operation or to ovariectomy
or orchidectomy. Lumbar vertebrae (L1 to L5) were removed fromSignaling to the Effects of Sex Steroids on Bone
female or male mice after 4 or 3 weeks, respectively. ApoptoticBone remodeling consists of focal cycles of resorption
osteoblasts and osteocytes were detected in undecalcified plastic-followed by formation. The rate of turnover depends
embedded sections by TUNEL staining using the Klenow FragEL
on the number of cycles, but the effect on bone mass detection kit (Oncogene), as previously described (Weinstein et al.,
depends on the focal balance within each cycle. Consis- 1998; Jilka et al., 1999).
tent with the in vitro antiapoptotic effects of sex steroids
on osteoblasts and osteocytes, we have shown in this Cell Cultures
paper that loss of estrogens or androgens shortens the Osteoblastic cells were obtained from neonatal murine calvaria and
cultured as previously described (Jilka et al., 1998). Osteocytic MLO-lifespan of osteoblasts and osteocytes in gonadecto-
Y4 cells, osteoblastic OB-6 cells and HeLa cells were cultured inmized mice from either sex. An increase in osteocyte
phenol red–free aMEM as previously described (Pottratz et al., 1994;apoptosis following loss of estrogen has been demon-
Kato et al., 1997; Lecka-Czernik et al., 1999).
strated previously in rats as well as in humans (Noble
and Reeve, 2000). In contrast to these effects, estrogens
Quantification of Apoptotic Cells In Vitro
exert proapoptotic effects on osteoclasts and estrogen Apoptotic cells were quantified either by trypan blue staining or by
deficiency prolongs their lifespan (Hughes et al., 1996; direct visualization of changes in nuclear morphology (in the case
of transfected HeLa cells), as previously described (Plotkin et al.,Kameda et al., 1997). A shortened working life of the
1999; Jilka et al., 1998, 1999). In the latter method, the visualizationbone-forming cells and longer working life of the bone-
of pyknotic or fragmented nuclei was facilitated by cotransfectionsresorbing cells could account for the focal imbalance
of cells plated on glass coverslips with the enhanced fluorescentbetween bone resorption and formation that follows loss
proteins (green or red) containing a nuclear localization sequence
of sex steroids. Moreover, an increase in osteocyte (Nuc-EGFP or Nuc-ERFP). Following fixation in 3.7% formaldehyde,
apoptosis could further weaken the skeleton by impair- the percentage of apoptosis was determined by determining the
nuclear morphology in 200–500 transfected (fluorescent) cells. Dataing the osteocyte/canalicular mechanosensory network
are presented either as absolute numbers of apoptotic cells, or as(Manolagas, 2000). In fact, it is likely that the signals
percentage of stimulus-induced apoptosis in the absence of sexof estrogens and those of mechanical strains may be
steroids. The formula used to calculate the percentage of etoposide-integrated in bone since osteocytes, which, like endo-
(or anoikis)-induced apoptosis is as follows:
thelial cells, are primarily regulated by shear stress and
respond to estrogens, do also respond to stretching % DCe 1 s 2 % DCv
% DCe 2 % DCv
3 100
with ERK activation (unpublished data). Finally, even
though in these studies we have linked the Src/Shc/ where DC 5 dead cells, e 5 etoposide, s 5 steroid-treated cultures,
ERK pathway with prevention of apoptosis, it is likely and v 5 vehicle-treated cultures.
that through the same mechanism, sex steroids may
also potentiate the actions of cytokines or growth fac- Anoikis Assay
OB-6 cells (3.3 3 105/ml) were cultured in type I collagen gels, astors acting through the same pathway in osteoblasts
previously described (Klein et al., 1991). Anoikis was initiated byand osteocytes and probably other cell types.
detaching the gels from the bottom of the well. After fixation andIn closing, we suggest that the antiapoptotic effects
embedding in paraffin, ten micron sections were cut and apoptotic
of sex steroids on osteoblasts and osteocytes due to cells were quantified by TUNEL staining.
a novel mechanism of estrogen and androgen action,
distinct from the highly specific transcriptional acti- Western Blot Analysis
vating events associated with classical sex hormone/ The phosphorylation status of ERK1/2 was analyzed by immunoblot-
ting using a mouse monoclonal antibody recognizing tyrosine phos-receptor interactions, may help to resolve some long
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